Compare Docusign Inc (DOCU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Neurocrine Biosciences Inc — how do they compare? Docusign Inc trades at $71 (market cap $12.88B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Docusign Inc and Neurocrine Biosciences Inc are close in size by market cap, and Docusign Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DOCU | NBIX | |
|---|---|---|
Market Cap | $12.88B | $14.60B |
Volume | 2,591,969 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $73.14 | $185.50 |
52-Week Low | $41.75 | $123.10 |
Typical Hold Time | 71 Days | 23 Days |
Enterprise Value | $12.28B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 4.71% with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows robust revenue growth reaching $2.98B in 2025 with improving profit margins, though valuation ratios remain elevated. Recent news highlights AI integration in contract processing and leadership recognition in workflow software.
Outlook remains positive with projected revenue growth to $3.4B in 2026, supported by AI adoption and operating leverage. Risks include insider selling, competitive pressures, and high valuation multiples. Analyst consensus is cautious with 64% hold ratings, but technical strength and fundamental improvements suggest potential for continued upside if execution persists.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
